Evidence map›Paper›PMID 26478219›Full record

ReviewCNS oncology2015

Genetics and imaging of oligodendroglial tumors.

Jonathan R Ellenbogen, Carol Walker, Michael D Jenkinson

Abstract readReview
In one paragraph

Review in CNS oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan R EllenbogenDepartment of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, L9 7LJ, UK.
Carol WalkerDepartment of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, L9 7LJ, UK.
Michael D JenkinsonDepartment of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, L9 7LJ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligodendroglial tumors are chemosensitive with a favorable prognosis compared with other histological subtypes. The genetic hallmark of co-deletion of 1p and 19q determines both treatment response and prognosis. While this test now forms part of routine histopathology diagnosis in many laboratories, alternative noninvasive imaging biomarkers of tumor genotype remain an attractive proposition. This review will focus on imaging biomarkers of molecular genetics in oligodendroglial tumors.

Indexed as

NeuroimagingBrain NeoplasmsChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 9HumansOligodendrogliomagenotypeMRIoligoastrocytomaoligodendrogliomaSPECT

Identifiers

PMID26478219
PMCPMC6082330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.